Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications

被引:60
作者
Bian, Yuemin [1 ,2 ,3 ,4 ]
Xie, Xiang-Qun [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Sch Pharm, Computat Chem Genom Screening Ctr, Pittsburgh, PA 15261 USA
[3] Univ Pittsburgh, NIH, Natl Ctr Excellence Computat Drug Abuse Res, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Drug Discovery Inst, Pittsburgh, PA 15261 USA
[5] Univ Pittsburgh, Sch Med, Dept Computat Biol, Pittsburgh, PA 15261 USA
[6] Univ Pittsburgh, Sch Med, Dept Struct Biol, Pittsburgh, PA 15261 USA
来源
AAPS JOURNAL | 2018年 / 20卷 / 03期
关键词
fragment-based drug design; fragment database; drug discovery; fragment docking; virtual screening; DE-NOVO DESIGN; MOLECULAR DOCKING; GENETIC ALGORITHM; INFORMATICS; FLEXIBILITY; GENERATION; INHIBITORS; DISCOVERY; LIBRARIES; FAMILY;
D O I
10.1208/s12248-018-0216-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fragment-based drug design (FBDD) has become an effective methodology for drug development for decades. Successful applications of this strategy brought both opportunities and challenges to the field of Pharmaceutical Science. Recent progress in the computational fragment-based drug design provide an additional approach for future research in a time-and labor-efficient manner. Combining multiple in silico methodologies, computational FBDD possesses flexibilities on fragment library selection, protein model generation, and fragments/compounds docking mode prediction. These characteristics provide computational FBDD superiority in designing novel and potential compounds for a certain target. The purpose of this review is to discuss the latest advances, ranging from commonly used strategies to novel concepts and technologies in computational fragment-based drug design. Particularly, in this review, specifications and advantages are compared between experimental and computational FBDD, and additionally, limitations and future prospective are discussed and emphasized.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Recent advances in Fragment-based strategies against tuberculosis
    Villemagne, Baptiste
    Tangara, Salia
    Willand, Nicolas
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 258
  • [42] Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge
    Kumar, Ashutosh
    Zhang, Kam Y. J.
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2012, 26 (05) : 603 - 616
  • [43] In Silico Fragment Screening by Replica Generation (FSRG) Method for Fragment-Based Drug Design
    Fukunishi, Yoshifumi
    Mashimo, Tadaaki
    Orita, Masaya
    Ohno, Kazuki
    Nakamura, Haruki
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2009, 49 (04) : 925 - 933
  • [44] Applications of 19F-NMR in Fragment-Based Drug Discovery
    Norton, Raymond S.
    Leung, Eleanor W. W.
    Chandrashekaran, Indu R.
    MacRaild, Christopher A.
    MOLECULES, 2016, 21 (07)
  • [45] Experiences in fragment-based drug discovery
    Murray, Christopher W.
    Verdonk, Marcel L.
    Rees, David C.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (05) : 224 - 232
  • [46] ELECTRON DENSITY GUIDED FRAGMENT-BASED DRUG DESIGN-A LEAD GENERATION EXAMPLE
    Abad, Marta C.
    Gibbs, Alan C.
    Zhang, Xuqing
    FRAGMENT-BASED DRUG DESIGN: TOOLS, PRACTICAL APPROACHES, AND EXAMPLES, 2011, 493 : 487 - 508
  • [47] Current perspectives in fragment-based lead discovery (FBLD)
    Lamoree, Bas
    Hubbard, Roderick E.
    STRUCTURE-BASED DRUG DESIGN: INSIGHTS FROM ACADEMIA AND INDUSTRY, 2017, 61 (05): : 453 - 464
  • [48] Implications of Fragment-Based Drug Discovery in Tuberculosis and HIV
    Mallakuntla, Mohan Krishna
    Togre, Namdev S.
    Santos, Destiny B.
    Tiwari, Sangeeta
    PHARMACEUTICALS, 2022, 15 (11)
  • [49] Targeting the ubiquitin system by fragment-based drug discovery
    Kennedy, Cassandra
    McPhie, Katherine
    Rittinger, Katrin
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [50] Development of Computational Approaches with a Fragment-Based Drug Design Strategy: In Silico Hsp90 Inhibitors Discovery
    Leon, Roberto
    Soto-Delgado, Jorge
    Montero, Elizabeth
    Vargas, Matias
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)